CD8A and cancer: Using immunogenomic approaches, it was documented that CD8+ T cells isolated from cancer patients’ blood could exert their reactivity against predicted neoepitopes almost 3 years after resection of the tumors [24], recommending a straightforward link between memory T cells and the gut microbiota that together participate in achieving a favorable clinical outcome.